Executive Development Programme in Regulatory Affairs for Advanced Therapies

-- ViewingNow

The Executive Development Programme in Regulatory Affairs for Advanced Therapies is a certificate course designed to meet the surging industry demand for experts in this field. This programme emphasizes the importance of regulatory compliance and strategic planning in the development and commercialization of advanced therapies like cell and gene therapies, tissue engineering, and biotechnological products.

4.0
Based on 2,965 reviews

2,479+

Students enrolled

GBP £ 140

GBP £ 202

Save 44% with our special offer

Start Now

ใ“ใฎใ‚ณใƒผใ‚นใซใคใ„ใฆ

By enrolling in this course, learners will gain essential skills in regulatory affairs, equipping them with the knowledge required to navigate the complex regulatory landscape and ensure adherence to global standards. The course content covers critical areas including regulatory strategies for advanced therapies, clinical trial regulations, quality management systems, and pharmacovigilance. As the biotechnology and pharmaceutical industries continue to grow, there is an increasing need for professionals who can effectively manage regulatory affairs for advanced therapies. By completing this course, learners will enhance their career prospects, gain a competitive edge, and contribute positively to the development of innovative therapies that improve patients' lives.

100%ใ‚ชใƒณใƒฉใ‚คใƒณ

ใฉใ“ใ‹ใ‚‰ใงใ‚‚ๅญฆ็ฟ’

ๅ…ฑๆœ‰ๅฏ่ƒฝใช่จผๆ˜Žๆ›ธ

LinkedInใƒ—ใƒญใƒ•ใ‚ฃใƒผใƒซใซ่ฟฝๅŠ 

ๅฎŒไบ†ใพใง2ใƒถๆœˆ

้€ฑ2-3ๆ™‚้–“

ใ„ใคใงใ‚‚้–‹ๅง‹

ๅพ…ๆฉŸๆœŸ้–“ใชใ—

ใ‚ณใƒผใ‚น่ฉณ็ดฐ

โ€ข Regulatory Landscape for Advanced Therapies
โ€ข Understanding ATMPs (Advanced Therapy Medicinal Products): Gene Therapy, Somatic Cell Therapy, and Tissue Engineering
โ€ข Current Good Manufacturing Practice (cGMP) for Advanced Therapies
โ€ข Clinical Trial Design, Regulations, and Processes for Advanced Therapies
โ€ข Pharmacovigilance and Safety Monitoring for Advanced Therapies
โ€ข Regulatory Pathways and Approval Processes for Advanced Therapies in Key Markets (EU, US, Japan, etc.)
โ€ข Quality Management Systems (QMS) for Advanced Therapies
โ€ข Post-Marketing Surveillance and Life Cycle Management of Advanced Therapies
โ€ข Current and Emerging Trends in Regulatory Affairs for Advanced Therapies

ใ‚ญใƒฃใƒชใ‚ขใƒ‘ใ‚น

ๅ…ฅๅญฆ่ฆไปถ

  • ไธป้กŒใฎๅŸบๆœฌ็š„ใช็†่งฃ
  • ่‹ฑ่ชžใฎ็ฟ’็†Ÿๅบฆ
  • ใ‚ณใƒณใƒ”ใƒฅใƒผใ‚ฟใƒผใจใ‚คใƒณใ‚ฟใƒผใƒใƒƒใƒˆใ‚ขใ‚ฏใ‚ปใ‚น
  • ๅŸบๆœฌ็š„ใชใ‚ณใƒณใƒ”ใƒฅใƒผใ‚ฟใƒผใ‚นใ‚ญใƒซ
  • ใ‚ณใƒผใ‚นๅฎŒไบ†ใธใฎ็Œฎ่บซ

ไบ‹ๅ‰ใฎๆญฃๅผใช่ณ‡ๆ ผใฏไธ่ฆใ€‚ใ‚ขใ‚ฏใ‚ปใ‚ทใƒ“ใƒชใƒ†ใ‚ฃใฎใŸใ‚ใซ่จญ่จˆใ•ใ‚ŒใŸใ‚ณใƒผใ‚นใ€‚

ใ‚ณใƒผใ‚น็Šถๆณ

ใ“ใฎใ‚ณใƒผใ‚นใฏใ€ใ‚ญใƒฃใƒชใ‚ข้–‹็™บใฎใŸใ‚ใฎๅฎŸ็”จ็š„ใช็Ÿฅ่ญ˜ใจใ‚นใ‚ญใƒซใ‚’ๆไพ›ใ—ใพใ™ใ€‚ใใ‚Œใฏ๏ผš

  • ่ชๅฏใ•ใ‚ŒใŸๆฉŸ้–ขใซใ‚ˆใฃใฆ่ชๅฎšใ•ใ‚Œใฆใ„ใชใ„
  • ่ชๅฏใ•ใ‚ŒใŸๆฉŸ้–ขใซใ‚ˆใฃใฆ่ฆๅˆถใ•ใ‚Œใฆใ„ใชใ„
  • ๆญฃๅผใช่ณ‡ๆ ผใฎ่ฃœๅฎŒ

ใ‚ณใƒผใ‚นใ‚’ๆญฃๅธธใซๅฎŒไบ†ใ™ใ‚‹ใจใ€ไฟฎไบ†่จผๆ˜Žๆ›ธใ‚’ๅ—ใ‘ๅ–ใ‚Šใพใ™ใ€‚

ใชใœไบบใ€…ใŒใ‚ญใƒฃใƒชใ‚ขใฎใŸใ‚ใซ็งใŸใกใ‚’้ธใถใฎใ‹

ใƒฌใƒ“ใƒฅใƒผใ‚’่ชญใฟ่พผใฟไธญ...

ใ‚ˆใใ‚ใ‚‹่ณชๅ•

ใ“ใฎใ‚ณใƒผใ‚นใ‚’ไป–ใฎใ‚ณใƒผใ‚นใจๅŒบๅˆฅใ™ใ‚‹ใ‚‚ใฎใฏไฝ•ใงใ™ใ‹๏ผŸ

▼

ใ‚ณใƒผใ‚นใ‚’ๅฎŒไบ†ใ™ใ‚‹ใฎใซใฉใ‚Œใใ‚‰ใ„ๆ™‚้–“ใŒใ‹ใ‹ใ‚Šใพใ™ใ‹๏ผŸ

▼

WhatSupportWillIReceive

▼

IsCertificateRecognized

▼

WhatCareerOpportunities

▼

ใ„ใคใ‚ณใƒผใ‚นใ‚’้–‹ๅง‹ใงใใพใ™ใ‹๏ผŸ

▼

ใ‚ณใƒผใ‚นใฎๅฝขๅผใจๅญฆ็ฟ’ใ‚ขใƒ—ใƒญใƒผใƒใฏไฝ•ใงใ™ใ‹๏ผŸ

▼

ใ‚ณใƒผใ‚นๆ–™้‡‘

ๆœ€ใ‚‚ไบบๆฐ—
ใƒ•ใ‚กใ‚นใƒˆใƒˆใƒฉใƒƒใ‚ฏ๏ผš GBP £140
1ใƒถๆœˆใงๅฎŒไบ†
ๅŠ ้€Ÿๅญฆ็ฟ’ใƒ‘ใ‚น
  • ้€ฑ3-4ๆ™‚้–“
  • ๆ—ฉๆœŸ่จผๆ˜Žๆ›ธ้…้”
  • ใ‚ชใƒผใƒ—ใƒณ็™ป้Œฒ - ใ„ใคใงใ‚‚้–‹ๅง‹
Start Now
ใ‚นใ‚ฟใƒณใƒ€ใƒผใƒ‰ใƒขใƒผใƒ‰๏ผš GBP £90
2ใƒถๆœˆใงๅฎŒไบ†
ๆŸ”่ปŸใชๅญฆ็ฟ’ใƒšใƒผใ‚น
  • ้€ฑ2-3ๆ™‚้–“
  • ้€šๅธธใฎ่จผๆ˜Žๆ›ธ้…้”
  • ใ‚ชใƒผใƒ—ใƒณ็™ป้Œฒ - ใ„ใคใงใ‚‚้–‹ๅง‹
Start Now
ไธกๆ–นใฎใƒ—ใƒฉใƒณใซๅซใพใ‚Œใ‚‹ใ‚‚ใฎ๏ผš
  • ใƒ•ใƒซใ‚ณใƒผใ‚นใ‚ขใ‚ฏใ‚ปใ‚น
  • ใƒ‡ใ‚ธใ‚ฟใƒซ่จผๆ˜Žๆ›ธ
  • ใ‚ณใƒผใ‚นๆ•™ๆ
ใ‚ชใƒผใƒซใ‚คใƒณใ‚ฏใƒซใƒผใ‚ทใƒ–ไพกๆ ผ โ€ข ้š ใ‚ŒใŸๆ–™้‡‘ใ‚„่ฟฝๅŠ ่ฒป็”จใชใ—

ใ‚ณใƒผใ‚นๆƒ…ๅ ฑใ‚’ๅ–ๅพ—

่ฉณ็ดฐใชใ‚ณใƒผใ‚นๆƒ…ๅ ฑใ‚’ใŠ้€ใ‚Šใ—ใพใ™

ไผš็คพใจใ—ใฆๆ”ฏๆ‰•ใ†

ใ“ใฎใ‚ณใƒผใ‚นใฎๆ”ฏๆ‰•ใ„ใฎใŸใ‚ใซไผš็คพ็”จใฎ่ซ‹ๆฑ‚ๆ›ธใ‚’ใƒชใ‚ฏใ‚จใ‚นใƒˆใ—ใฆใใ ใ•ใ„ใ€‚

่ซ‹ๆฑ‚ๆ›ธใงๆ”ฏๆ‰•ใ†

ใ‚ญใƒฃใƒชใ‚ข่จผๆ˜Žๆ›ธใ‚’ๅ–ๅพ—

ใ‚ตใƒณใƒ—ใƒซ่จผๆ˜Žๆ›ธใฎ่ƒŒๆ™ฏ
EXECUTIVE DEVELOPMENT PROGRAMME IN REGULATORY AFFAIRS FOR ADVANCED THERAPIES
ใซๆŽˆไธŽใ•ใ‚Œใพใ™
ๅญฆ็ฟ’่€…ๅ
ใงใƒ—ใƒญใ‚ฐใƒฉใƒ ใ‚’ๅฎŒไบ†ใ—ใŸไบบ
London School of International Business (LSIB)
ๆŽˆไธŽๆ—ฅ
05 May 2025
ใƒ–ใƒญใƒƒใ‚ฏใƒใ‚งใƒผใƒณID๏ผš s-1-a-2-m-3-p-4-l-5-e
ใ“ใฎ่ณ‡ๆ ผใ‚’LinkedInใƒ—ใƒญใƒ•ใ‚ฃใƒผใƒซใ€ๅฑฅๆญดๆ›ธใ€ใพใŸใฏCVใซ่ฟฝๅŠ ใ—ใฆใใ ใ•ใ„ใ€‚ใ‚ฝใƒผใ‚ทใƒฃใƒซใƒกใƒ‡ใ‚ฃใ‚ขใ‚„ใƒ‘ใƒ•ใ‚ฉใƒผใƒžใƒณใ‚นใƒฌใƒ“ใƒฅใƒผใงๅ…ฑๆœ‰ใ—ใฆใใ ใ•ใ„ใ€‚
SSB Logo

4.8
ๆ–ฐ่ฆ็™ป้Œฒ
โ†’ ใ‚ณใƒผใ‚นใ‚’่ฆ‹ใ‚‹